<DOC>
	<DOC>NCT02431364</DOC>
	<brief_summary>This is a randomized, double-blind, sequential, dose-escalation, Phase 1 trial to evaluate the safety and tolerability of verdinexor. Verdinexor or placebo will be given on days 1 and 3 to healthy adult subjects.</brief_summary>
	<brief_title>Trial of Safety and Tolerability of Oral Verdinexor (KPT-335) in Healthy Adults</brief_title>
	<detailed_description>This is a randomized, double-blind, sequential, dose-escalation, Phase 1 trial to evaluate the safety and tolerability of verdinexor. Verdinexor or placebo will be given on days 1 and 3 to healthy adult subjects. Cohorts of 8 subjects each (6 active, 2 placebo) will be sequentially administered verdinexor or placebo (one dose on Day 1 and one dose on Day 3) using a dose-escalation scheme. A conservative, sequential, dose-escalation strategy employing decreasing escalation increments will be used.</detailed_description>
	<criteria>Subjects must be in good health as determined by the investigator, based on the medical history, ECG, physical examination, and safety laboratory tests at screening. Subjects must be identified as a nonsmoker at the screening visit (a nonsmoker is defined as an individual who has abstained from smoking for at least 1 year prior to the screening visit and who has a â‰¤ 15 pack year history of lifetime cigarette use). A urine cotinine test will be performed at screening and at the time of clinic checkin prior to study drug treatment. The subject has any surgical or medical condition that potentially may alter the absorption, metabolism, or excretion of the study drug such as gastrectomy, Crohn's disease, or liver disease. The subject has a history of clinically significant allergies. Hay fever is allowed unless it is active or has required treatment within the previous 2 months. Presence of a chronic condition(s) with clinical or historical evidence of recent exacerbation, or other information to suggest noncontrol of such condition(s). History of alcohol abuse or drug addiction within 12 months of the screening visit. Any subject with active cataracts or medical history of cataracts.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>KPT-335</keyword>
	<keyword>Verdinexor</keyword>
	<keyword>Karyopharm</keyword>
	<keyword>First-in-Human</keyword>
	<keyword>Adult Subjects</keyword>
</DOC>